Gritgen Therapeutics Co., Ltd., a biotechnology company specializing in the discovery and development of cutting-edge gene therapy products, is pleased to announce the successful validation and official commencement of operations at its commercial Good Manufacturing Practices (GMP) facility located in Suzhou Industrial Park.

Fujirebio Holdings, Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (Headquarters: Kobe, Japan; President: Kaoru Asano) jointly announce a Basic Agreement on Business Collaboration to foster a multifaceted partnership encompassing research and development, production, clinical development, and sales-marketing in the field of immunoassay.

A major advancement in pharmaceutical cleanroom technology has been achieved with the launch of new automated systems.

The latest regulatory compliance guidelines impact clinical trials across Asia.

Thermo Fisher Scientific, the global leader in scientific services, has announced an expansion of its manufacturing capacity in St. Louis, aimed at supporting the production of biologic therapies for a wide range of diseases, including cancer, autoimmune conditions, and rare genetic disorders.

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in next-gen protein therapeutics, is pleased to announce the inauguration of its cutting-edge Current Good Manufacturing Practices (CGMP) drug substance facility located in the Ziggurat building (Echo Investment Capital) in Oklahoma City, OK.

GC Biopharma Corp. has officially announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its drug candidate, GC1126A, for the treatment of Thrombotic Thrombocytopenic Purpura (TTP). This significant development was finalized on September 27.

Partnership aims to innovate vaccine manufacturing efficiency in Singapore.

Expansion aims to boost production capacity in response to increasing market needs.

Shasqi, a clinical-stage biotech company specializing in improving the effectiveness of cancer drugs using click chemistry, has announced an expansion of its ongoing research collaboration with Johnson & Johnson Enterprise Innovation Inc.